Diacerein in the treatment of chronic musculoskeletal pain
https://doi.org/10.14412/1996-7012-2022-3-110-114
Abstract
Chronic musculoskeletal pain (MSP) is the most painful manifestation of rheumatic diseases (RD), the main cause of disability, a decrease in the quality and life expectancy of patients, which determines not only the high medical, but also the social significance of this problem. The chronic nature of the pain forces patients with MSP to use analgesic therapy for a long time. At the same time, non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for MSP. However, it is well known that the use of this group of drugs is associated with significant difficulties, mainly due to the comorbid pathology that is common in middle-aged and elderly people. In this regard, there are continuing attempts at searching for alternative agents for chronic MSP control, which have analgesic and anti-inflammatory activity similar to NSAIDs, but lack their side effects. Some researchers believe that diacerein can become such drug.
Supporting agencies: This article has been supported by Micro Labs Limited.
About the Authors
E. Yu. Polishchuk
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Elena Yurievna Polishchuk
34A, Kashirskoe shosse, Moscow 115522
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
References
1. Nasonov EL, Yakhno NN, Karateev AE, et al. General principles of treatment for musculoskeletal pain: Interdisciplinary consensus. Nauchno-Prakticheskaya Revmatologiya. 2016; 54(3):247-65. (In Russ.).
2. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2020. 448 p.
3. Bruyere O, Honvo G, Veronese N. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3): 337-50. doi: 10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.
4. Pelletier JP, Raynauld JP, Dorais M, et al. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology (Oxford). 2020 Dec 1; 59(12):3858-68. doi: 10.1093/rheumatology/keaa072.
5. Franchi-Micheli S, Lavacchi L, Friedmann CA, Zilletti L. The influence of rhein on the biosynthesis of prostaglandin-like substances in vitro. J Pharm Pharmacol. 1983 Apr;35(4):262-4. doi: 10.1111/j.2042-7158.1983.tb02929.x.
6. Almezgagi M, Zhang Y, Hezam K, et al. Diacerein: Recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother. 2020 Nov;131:110594. doi: 10.1016/j.biopha.2020.110594. Epub 2020 Aug 25.
7. Pelletier J, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10):2339-48. doi: 10.1002/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P.
8. Pavelka K, Trc T, Karpas K, et al. The Efficacy and Safety of Diacerein in the Treatment of Painful Osteoarthritis of the Knee. Arthritis Rheum. 2007 Dec;56(12):4055-64. doi: 10.1002/art.23056.
9. Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moзa Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 Feb 10;2:CD005117. doi: 10.1002/14651858.CD005117.pub3.
10. Louthrenoo W, Nilganuwong S, Aksaranugraha S, et al. The efficacy, safety and carry- over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis Cartilage. 2007 Jun;15(6): 605-14. doi: 10.1016/j.joca.2007.02.021. Epub 2007 Apr 19.
11. Zheng W, Tang F, Li J, et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J. 2006 Jun;21(2):75-80.
12. Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/ 527347/2014. https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-prac-assessment-report_en.pdf
13. Lapshina SA, Myasoutova LI, Salikhov IG, Vasil'ev AG. Evaluation of the efficacy and safety of the drug Arthroker (diacerein) in patients with osteoarthritis of the knee joint. Sovremennoe iskusstvo meditsiny. 2011;(2): 29-33. (In Russ.).
14. Zaigrova NK. Evaluation of the efficacy of Arthrocare® for knee osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(4):23-5. (In Russ.). doi: 10.14412/1996-7012-2013-2434.
15. Sharapova EP, Kashevarova NG, Zaitseva EM, et al. Evaluation of efficacy and safety of diacerein in patients with osteoarthritis of the hip joints. Meditsinskii sovet. 2017;(1S):84-90. (In Russ.).
16. Evstratova EF, Vasil'eva LV, Tolstykh EM, Zolotareva MA. Dynamic changes in clinical and laboratory symptoms of osteoarthritis severity as markers of rational treatment in outpatient settings. Aktual'nye nauchnye issledovaniya v sovremennom mire. 2019;(9-2): 24-9. (In Russ.).
17. Starodubtseva IA, Vasil'eva LV, Nikitin AV. Therapeutic approach using the drug arthroker in the treatment of secondary osteoarthritis in patients with rheumatoid arthritis. Klinicheskaya gerontologiya. 2013;(5):49-51. (In Russ.).
18. Uspenskii YuP, Ivanov SV, Fominykh YuA, Rakhov DA. The effect of diacerein on the clinical course of osteoarthritis and endothelial dysfunction in patients with arterial hypertension. Lechashchii vrach. 2018;(4):40-5. (In Russ.).
Review
For citations:
Polishchuk EY, Karateev AE. Diacerein in the treatment of chronic musculoskeletal pain. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(3):110-114. (In Russ.) https://doi.org/10.14412/1996-7012-2022-3-110-114
Views:
480
Email this article 